PURPOSE We wanted to determine whether providing home fecal occult blood test (FOBT) kits to eligible patients during infl uenza inoculation (fl u shot) clinics can contribute to higher colorectal cancer screening (CRCS) rates.
METHODSThe study was time randomized. On 8 dates of an annual fl u shot clinic at the San Francisco General Hospital, patients were offered fl u shots as usual (control group) and on 9 other dates, patients were offered both fl u shots and FOBT kits (intervention group).
RESULTSThe study included 514 patients aged 50 to 79 years, with 246 in the control group and 268 in the intervention group. At the conclusion of fl u season, FOBT screening rates increased by 4.4 percentage points from 52.9% at baseline to 57.3% (P = .07) in the control group, and increased by 29.8 percentage points from 54.5% to 84.3% (P <.001) in the intervention group, with the change among intervention participants 25.4 percentage points greater than among control participants (P value for change difference <.001). Among patients initially due for CRCS, 20.7% in the control group and 68.0% in the intervention group were up-to-date at the conclusion of the study (P <.001). In multivariate analyses, the odds ratio for becoming up-to-date with screening in the intervention group (vs the control group) was 11.3 (95% CI, 5.8-22.0).
CONCLUSIONSOffering FOBT kits during fl u shot clinics dramatically increased the CRCS rate for fl u shot clinic attendees. Pairing home FOBT kits with annual fl u shots may be a useful strategy to improve CRCS rates in other primary care or public health settings. Ann Fam Med 2009;7:17-23. DOI: 10.1370/afm.934.
INTRODUCTIONI ncidence of and mortality from colorectal cancer can be reduced with colorectal cancer screening (CRCS). 1 In the United States, recommended CRCS tests have long included the annual, guaiac-based, home fecal occult blood test (FOBT), fl exible sigmoidoscopy every 5 years, annual FOBT plus fl exible sigmoidoscopy every 5 years, doublecontrast barium enema every 5 years, or colonoscopy every 10 years. 2,3 Recently, fecal immunochemical testing, stool DNA testing, and computed tomographic colonoscopy have also been endorsed as screening methods.
4Despite these testing options, only slightly more than one-half of eligible adults aged 50 years and older report being up-to-date with CRCS.5 Partly as a result, colorectal cancer remains the second leading cause of cancer death in the United States.6 Primary care remains the most important access point for CRCS, 7 but primary care offi ces frequently lack systems to ensure that CRCS is offered when needed and to support patient adherence to tests that are ordered.
F OB T AT FLU CL INIC S INCR E A SES S CR EENINGcare is accompanied by special challenges. Financial constraints often limit the menu of screening options to FOBT, the least expensive CRCS test, with colonoscopy reserved for cases of abnormal FOBT results or other high-risk conditions. 13 The barriers to providing an annual FOBT may be magnifi ed by educational, ...